Corvus Pharmaceuticals CRVS Stock
Corvus Pharmaceuticals Price Chart
Corvus Pharmaceuticals CRVS Financial and Trading Overview
| Corvus Pharmaceuticals stock price | 1.53 USD |
| Previous Close | 1.38 USD |
| Open | 1.37 USD |
| Bid | 1.42 USD x 1100 |
| Ask | 1.44 USD x 1000 |
| Day's Range | 1.37 - 1.47 USD |
| 52 Week Range | 0.61 - 4.19 USD |
| Volume | 109.42K USD |
| Avg. Volume | 283.65K USD |
| Market Cap | 71.11M USD |
| Beta (5Y Monthly) | 1.071 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.88 USD |
CRVS Valuation Measures
| Enterprise Value | 40.63M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.9591837 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.6057587 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.766 |
Trading Information
Corvus Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.071 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 4.19 USD |
| 52 Week Low | 0.61 USD |
| 50-Day Moving Average | 1.41 USD |
| 200-Day Moving Average | 1.7 USD |
CRVS Share Statistics
| Avg. Volume (3 month) | 283.65K USD |
| Avg. Daily Volume (10-Days) | 375.78K USD |
| Shares Outstanding | 49.04M |
| Float | 36.88M |
| Short Ratio | 13.46 |
| % Held by Insiders | 4.09% |
| % Held by Institutions | 45.54% |
| Shares Short | 1.71M |
| Short % of Float | 4.63% |
| Short % of Shares Outstanding | 3.49% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.93% |
| Return on Equity (ttm) | -55.41% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -23001000 USD |
| Net Income Avi to Common (ttm) | -30192000 USD |
| Diluted EPS (ttm) | -0.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 32.17M USD |
| Total Cash Per Share (mrq) | 0.66 USD |
| Total Debt (mrq) | 1.69M USD |
| Total Debt/Equity (mrq) | 3.82 USD |
| Current Ratio (mrq) | 4.534 |
| Book Value Per Share (mrq) | 0.903 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -26315000 USD |
| Levered Free Cash Flow (ttm) | -18238250 USD |
Profile of Corvus Pharmaceuticals
| Country | United States |
| State | CA |
| City | Burlingame |
| Address | 863 Mitten Road |
| ZIP | 94010 |
| Phone | 650 900 4520 |
| Website | https://www.corvuspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29 |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
Q&A For Corvus Pharmaceuticals Stock
What is a current CRVS stock price?
Corvus Pharmaceuticals CRVS stock price today per share is 1.53 USD.
How to purchase Corvus Pharmaceuticals stock?
You can buy CRVS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Corvus Pharmaceuticals?
The stock symbol or ticker of Corvus Pharmaceuticals is CRVS.
Which industry does the Corvus Pharmaceuticals company belong to?
The Corvus Pharmaceuticals industry is Biotechnology.
How many shares does Corvus Pharmaceuticals have in circulation?
The max supply of Corvus Pharmaceuticals shares is 49.04M.
What is Corvus Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Corvus Pharmaceuticals PE Ratio is now.
What was Corvus Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Corvus Pharmaceuticals EPS is -0.56 USD over the trailing 12 months.
Which sector does the Corvus Pharmaceuticals company belong to?
The Corvus Pharmaceuticals sector is Healthcare.
Corvus Pharmaceuticals CRVS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
- {{ link.label }} {{link}}